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There is no doubt that current antirheumatic drugs are better than placebos in prospective placebo controlled clinical trials in rheumatoid arthritis (RA). This has been shown for non-steroidal antiinflammatory drugs and slow acting antirheumatic drugs.1 Studies of the natural history of treated RA in patients seen in specialist clinics and followed up for 10-20 years24 show, however, that the disease causes excessive mortality and significant morbidity.
What is the best treatment plan? In some clinical situations it is easy to evaluate the best approaches to management; for example, patients with a serious head injury either live or die,5 6 and treatment policies which influence outcome can be developed using this. The ability to divide patients with RA into therapeutic successes or failures is an equally important prerequisite for evaluating rheumatological treatment. A classification of response to treatment is useful both in assessment within clinical trials and in individual patient management.
A consensus meeting was held at St Bartholomew's Hospital to consider which measures should be used and how much weight should be attached to them. The meeting involved 15 rheumatological workers from nine centres with special interests in the area of disease assessment and took the form of an extended round table discussion to achieve a reconciled assessment of opinion: a true Accepted for publication 21 The group's overall view, reached with considerable, almost surprising, unanimity, was that there are five categories of measure relevant to the outcome of RA (Table 2 ). These are relevant over different time scales-the short term including time periods of one or two years and the long term of one or two decades. No measure should be considered entirely in isolation, but they may be relatively independent of each other. The importance of mortality, severe morbidity, and functional impairment outweighs clinical and laboratory indices of disease activity.
Responses to slow acting antirheumatic drugs
Analgesics and non-steroidal anti-inflammatory drugs have only short term symptom relieving effects and are not relevant to the determination of disease outcome except in a negative sensetoxicity. By contrast, slow acting antirheumatic drugs, such as gold and penicillamine, have the potential to influence the course of RA. How should 20 These showed that treatment is better with a slow acting drug than with placebo, but they gave limited information about the extent of improvement in any given patient. They did not allow for standardisation of response.
The American Rheumatism Association remission criteria can serve as a basis for formulating different response scales.'8 These criteria consist of six requirements: morning stiffness of 15 minutes or less; no fatigue; no joint pain; no joint tenderness; no soft tissue swelling; and ESR <30 mm/h in women and <20 mm/h in men. They can be modified to determine varying degrees of response. The first step is to abandon those components which cannot be readily measured, such as fatigue.
Secondly, joint tenderness and swelling should be considered together as they are often difficult to dissociate. This leaves three clinical and one laboratory variable: morning stiffness; joint pain; joint tenderness/swelling; and ESR. Together they can be used to give a set of response criteria (Table 3) . Despite the problems associated with their measurement (outlined in Table 1 ) these variables were Death is the final outcome of disease, and evidence that RA leads to increased mortality is 
